Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Whitmore

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
The Journal of Urology|December 21, 2012
An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancerRobert C Flanigan, Anthony J Polcari, Neil D Shore, et al.
British Journal of Pharmacology|December 22, 1999
Pharmacological characterization of antagonists of the C5a receptorN J Paczkowski, A M Finch, J B Whitmore, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 2, 2020
TNF-α signaling regulates RUNX1 function in endothelial cellsHannah A B Whitmore, Dhanesh Amarnani, Michael O'Hare, et al.
The American Journal of Pathology|December 21, 2020
Treatment of Experimental Choroidal Neovascularization via RUNX1 InhibitionLucia Gonzalez-Buendia, Santiago Delgado-Tirado, Miranda An, et al.
Arthritis and Rheumatism|May 30, 2006
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritisDaniel J Lovell, Andreas Reiff, Olcay Y Jones, et al.
The Journal of Infectious Diseases|October 7, 2000
A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDSC Brites, M J Gilbert, D Pedral-Sampaio, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2012
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerNadeem A Sheikh, Daniel Petrylak, Philip W Kantoff, et al.
Current Medical Research and Opinion|January 6, 2006
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyAllan Gibofsky, William R Palmer, John A Goldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical OutcomeDebraj GuhaThakurta, Nadeem A Sheikh, Li-Qun Fan, et al.
The American Journal of Pathology|April 24, 2021
Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host MediatorsMichael O'Hare, Dhanesh Amarnani, Hannah A B Whitmore, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Urology|December 21, 2012
An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancerRobert C Flanigan, Anthony J Polcari, Neil D Shore, et al.
British Journal of Pharmacology|December 22, 1999
Pharmacological characterization of antagonists of the C5a receptorN J Paczkowski, A M Finch, J B Whitmore, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 2, 2020
TNF-α signaling regulates RUNX1 function in endothelial cellsHannah A B Whitmore, Dhanesh Amarnani, Michael O'Hare, et al.
The American Journal of Pathology|December 21, 2020
Treatment of Experimental Choroidal Neovascularization via RUNX1 InhibitionLucia Gonzalez-Buendia, Santiago Delgado-Tirado, Miranda An, et al.
Arthritis and Rheumatism|May 30, 2006
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritisDaniel J Lovell, Andreas Reiff, Olcay Y Jones, et al.
The Journal of Infectious Diseases|October 7, 2000
A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDSC Brites, M J Gilbert, D Pedral-Sampaio, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2012
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerNadeem A Sheikh, Daniel Petrylak, Philip W Kantoff, et al.
Current Medical Research and Opinion|January 6, 2006
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyAllan Gibofsky, William R Palmer, John A Goldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical OutcomeDebraj GuhaThakurta, Nadeem A Sheikh, Li-Qun Fan, et al.
The American Journal of Pathology|April 24, 2021
Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host MediatorsMichael O'Hare, Dhanesh Amarnani, Hannah A B Whitmore, et al.
Pageof 6